Dove Medical Press podcasts

This podcast episode reviews recent advances in the treatment of IDH1-mutant acute myeloid leukemia (AML), focusing on the mechanisms, efficacy, and safety profiles of approved IDH1 inhibitors. The purpose is to present expert insights and clinical data from key trials that underscore the clinical benefits of these targeted therapies. Through discussion of key findings from pivotal clinical trial studies, including data supporting the use of these agents in both newly diagnosed and relapsed or refractory (R/R) settings, the episode highlights significant outcomes such as increased overall response and prolonged duration of remission in patients treated with IDH1 inhibitors. The analysis examines critical factors including treatment sequencing, combination regimens, and toxicity management, particularly the monitoring and mitigation of differentiation syndrome and QT interval prolongation. Emphasis is placed on the clinical rationale for individualized therapy selection and the importance of repeat mutation testing at diagnosis and relapse to guide treatment decisions. The results obtained from these clinical trials provide evidence that integrating oral targeted agents into the management of relapsed or refractory AML improves patient outcomes, especially for older or unfit patients who cannot undergo intensive chemotherapy. In conclusion, the episode demonstrates that the evolving use of IDH1 inhibitors, supported by rigorous clinical evidence, represents a promising advance in AML treatment by offering more precise, effective, and tolerable therapeutic options.

Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by diverse genetic mutations, including IDH1 and IDH2, which are present in approximately 15-20% of cases. Recent clinical practice guidelines, including the 2025 NCCN guidelines, emphasize the importance of comprehensive mutational profiling at diagnosis and at relapse to guide targeted treatment strategies for patients with refractory or relapsed (R/R) AML. IDH1-mutations, which occur in 5-7% of AML cases, result in the production of the oncometabolite 2-hydroxyglutarate (2-HG), disrupting cellular differentiation. IDH1-inhibitors, such as ivosidenib and olutasidenib, block this aberrant metabolic pathway, allowing for differentiation and apoptosis of leukemia cells. Given the rarity of these mutations, comprehensive molecular testing remains essential to optimize therapeutic decision-making.

Experts from Yale Cancer Center and MD Anderson Cancer Center describe the evolving landscape of molecular diagnostics in acute myeloid leukemia (AML). The discussion traces the shift from morphology- and immunophenotype-based classification to genomics-driven stratification, catalyzed by advancements in next-generation sequencing (NGS). Discussants emphasize the clinical importance of identifying key genetic mutations—such as FLT3, IDH1/2, TP53, NPM1, KMT2A, and NUP98—to inform prognosis and guide use of targeted therapies. They review the sensitivity and applications of testing modalities including Sanger sequencing, NGS, PCR, and capillary electrophoresis, and highlight how combining DNA and RNA analyses enhances detection of both mutations and gene fusions. Practical insights are offered on assay selection, test interpretation, and turnaround times, noting that while NGS is generally adequate for most targets, single-gene PCR may be needed for urgent decision-making. The episode concludes by underscoring the need for oncologists to partner with pathologists and review test coverage data to ensure appropriate molecular profiling. These insights support the integration of precise molecular diagnostics into routine AML management, enhancing personalized therapy and improving clinical outcomes.

Generalized pustular psoriasis (GPP) is a rare, chronic, inflammatory skin disease characterized by persistent symptoms and sudden flares of painful, sterile pustules, and may be accompanied by systemic inflammation. Ongoing symptoms of GPP can have a serious impact on patient quality of life, morbidity, and mortality, and severe flares may be life-threatening if left untreated. Guidelines have been developed for the treatment of GPP flares; however, health care professionals and patients are lacking guidance on the management of long-term, persistent symptoms of GPP. Spesolimab is the only FDA-approved treatment for GPP and is approved for use in adults and pediatric patients aged 12 years or older and weighing at least 40 kg. Spesolimab recently gained FDA approval as a subcutaneous injection to treat GPP when patients are not experiencing a flare. In this podcast episode, we discuss what is known about the chronic disease burden of GPP and how persistent symptoms affect quality of life when patients are not experiencing a flare. We address the need for treatment guidelines for chronic GPP and discuss the results of the EFFISAYIL® 2 clinical trial, which led to the approval of the subcutaneous formulation of spesolimab to treat GPP when patients are not experiencing a flare. Finally, we discuss what can be done to improve the treatment of patients with chronic GPP, both while experiencing a flare, and while living with persistent symptoms.

Dr Uwe Wollina, the former head of the department of dermatology and allergology at the Academic Teaching Hospital, Dresden welcome Drs. Merola and Amin to discuss the potential triggers of an acute GPP flare. GPP can be debilitating for patients, and they will discuss the different aspects of the burden of disease for patients with GPP. Generalized pustular psoriasis (GPP) is the most severe form of pustular psoriasis and affects large areas of the body. GPP is a rare disease, and has a variable presentation; thus, its diagnosis is challenging. The onset of symptoms is rapid, with the appearance of painful skin erythema, followed by the widespread eruption of sterile pustules. Acute GPP (called a flare) is often accompanied by systemic symptoms, including high fever, pain in skin lesions, malaise, and fatigue. Approximately half of GPP flares require hospitalization, with an average inpatient duration of 10–14 days. GPP prevalence estimates range from approximately 2–124 cases per million persons, with a female predominance. The most common age of onset of GPP is 40–60 years, although cases have been described in younger adults and children. GPP affects every aspect of patients’ lives and has a high physical and psycho-social impact. Recent research on the interleukin-36 pathway associated with GPP led to the development of a GPP-specific treatment, spesolimab, which was approved by the US FDA in September 2022. This podcast explores the clinical presentation, disease course, and burden of disease in GPP, including differential diagnosis and common triggers of an acute flare.

Dr Jason Hawkes, a board-certified medical dermatologist in the Greater Sacramento area welcomes Drs. Bhutani and Reisner, to discuss the clinical presentation of GPP, the patient journey, diagnostic challenges, and novel management strategies from the perspective of the patient and provider. Generalized pustular psoriasis (GPP) is a rare, chronic, and debilitating disease characterized by flares of widespread erythema, desquamation, and pustule formation. GPP flares can be accompanied by systemic symptoms including fever, fatigue, malaise, and skin pain; severe cases may be fatal if untreated. Although GPP may occur concurrently with plaque psoriasis, they represent two distinct inflammatory conditions. Patients with GPP experience a substantial burden of disease, and the impact of GPP on an individual’s mental health and quality-of-life (QoL) goes far beyond skin pain and discomfort. The rarity of GPP may result in a misdiagnosis, as the sudden onset of skin pustules may be mistaken for a primary infection. Misdiagnosis with a subsequent delay in treatment has tremendous negative consequences for the affected patient. In September 2022, spesolimab became the first FDA-approved medication in the US for the treatment of GPP flares in adults. Spesolimab has since been approved by regulatory agencies in numerous countries, including Japan, Mainland China, and the EU. Prior to spesolimab, the clinical management of GPP relied on the off-label use of systemic or biologic therapies approved for plaque psoriasis or other inflammatory conditions. There is a need for increased education among healthcare providers regarding the clinical diagnosis, risk stratification, and therapeutic management of this rare disease, including the other novel GPP-specific therapies in development. In this podcast, two dermatologists and a patient who has plaque psoriasis and GPP discuss the clinical presentation, symptoms, disease burden, QoL impacts, diagnostic challenges, and therapeutic strategies for the management of GPP.

Dr Stanley Cohen, the Department of Internal Medicine, University of Texas Southwestern Medical Center, and Mariah Z. Leach, Mamas Facing Forward, Colorado, discuss some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis following the US 2023 release of several biosimilars of the adalimumab reference product, also known by the brand name, Humira. The podcast also covers the difference between a generic medicine and a biosimilar, and the clinical evidence to support the safety and efficacy of adalimumab biosimilars in patients with rheumatoid arthritis. This podcast is intended for health care professionals and patients with the aim of discussing some of the concerns that patients may have about initiating treatment with a biosimilar, or switching from their current medication to a biosimilar, for Rheumatoid Arthritis. The podcast also covers the definitions of a biosimilar, interchangeable biosimilar, and switching, before discussing the available data supporting the efficacy and safety of biosimilars in Rheumatoid Arthritis. The authors of this podcast include Stanley Cohen, MD, Professor at University of Texas Southwestern Dallas, TX, and Mariah Z. Leach, who is a patient advocate and the founder of Mamas Facing Forward in Louisville, Colorado. This podcast has not been peer-reviewed but has been vetted by the journal’s Editor-in-Chief.  Content and technical support were provided by Envision Pharma Group, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI). for these services. BIPI was given the opportunity to review earlier talking points and the final transcript for medical and scientific accuracy, as well as intellectual property considerations. Copyright © 2023, Boehringer Ingelheim Pharmaceuticals, Inc.. All rights reserved.

Dr Uwe Wollina, the head of the department of dermatology and allergology at the Academic Teaching Hospital, Dresden welcome Drs. Clive Liu and Eingun James Song, who are both dermatologists in Washington State to discuss their experiences in treating generalized pustular psoriasis, also referred to as GPP. Acute episodes of generalized pustular psoriasis (GPP), known as “flares,” are characterized by the widespread appearance of pustules with surrounding skin erythema, and are often accompanied by systemic symptoms. The clinical course of GPP is unpredictable, and symptoms vary in extent and severity; the disease may be relapsing-remitting with recurrent episodes of pustulosis, or be more persistent. The triggers that may lead to flares include withdrawal of corticosteroids, stress, pregnancy, and infections. GPP-specific assessment tools, such as the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) and the General Pustular Psoriasis Area and Severity Index (GPPASI), were developed to evaluate the severity of disease, and to monitor the patient’s response to therapy during clinical trials. Spesolimab is the first GPP-specific treatment available in the United States for the treatment of GPP flares in adults, and was approved by the US FDA in September 2022. To date, spesolimab has been approved by regulatory agencies in almost 40 countries, including Japan, Mainland China, and the European Union. Spesolimab is a first-in-class humanized monoclonal antibody that targets the interleukin-36 receptor, and blocks the downstream effects of the interleukin-36 pathway, which is associated with GPP pathogenesis. Data from clinical trials demonstrate the safety and efficacy of spesolimab in providing rapid clinical improvement for patients with GPP flares. Standardized international guidelines for the diagnosis and management of GPP are needed, and no recent GPP guidelines are available in the US. This podcast discusses clinical assessment tools for GPP (GPPGA and GPPASI), the evolution of GPP management guidelines, the therapeutic landscape of GPP, efficacy and safety data for spesolimab, and examines important considerations for patients living with this condition.

Dr Uwe Wollina, the head of the department of dermatology and allergology at the Academic Teaching Hospital, Dresden welcome Drs. Bhutani and Hawkes, both board-certified dermatologists in California to discuss their experiences in treating generalized pustular psoriasis, also referred to as GPP. Generalized pustular psoriasis is a rare presentation of psoriatic disease and is characterized by the acute onset of diffuse superficial pustules on the skin. These pustules can often coalesce, forming what’s known as ‘lakes of pus’ that are most often seen on the trunk and on skin folds. GPP flares are often accompanied by systemic symptoms, including fever, malaise, and edema. The interleukin (IL)-36 pathway plays a central role in the development of GPP, although several other genes may be associated with GPP. The rarity of GPP makes its diagnosis challenging and it could be mistaken for an infectious condition or other types of pustular psoriasis, including unstable forms of psoriasis that may present with pustules. Performing a thorough skin examination and obtaining a detailed history are vital to exclude these differential diagnoses. Incorrect or late diagnosis, inadequate or delayed treatment, and lack of specialist referrals may contribute to increased disease severity and can have a debilitating impact on patients’ quality of life. In this podcast, two US-based dermatologists discuss the clinical characteristics of GPP, highlight the central role of IL-36 in immunopathogenesis, and share practical approaches to recognizing and diagnosing the disease.

Dr John Kane, discusses negative symptoms in schizophrenia alongside fellow expert, Dr William Carpenter, and Mr Matthew Racher, a Certified Recovery Peer Specialist and dedicated advocate for people living with schizophrenia, who is currently studying for his Master of Social Work (MSW) in Miami, Florida. In this podcast, the authors discuss challenges and opportunities faced by patients and clinicians in the assessment and treatment of negative symptoms. They also touch upon emerging therapeutic strategies, with the aim of raising awareness of the unmet therapeutic needs of those living with negative symptoms. Mr Racher provides a unique patient perspective to this discussion, drawing on his own daily experiences of living with negative symptoms, as well as offering positive insights from his recovery from schizophrenia. Author Biographies Dr John Kane is Professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, a recipient of the Arthur P. Noyes Award in Schizophrenia, the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz E. Lehmann Research Award from New York State, and the Dean Award from the American College of Psychiatrists. Dr William Carpenter, MD, is a professor of psychiatry at the University of Maryland School of Medicine, is Editor-in-Chief for Schizophrenia Bulletin. Dr Carpenter’s main research focus is in the area of schizophrenia, and was awarded The Rhoda and Bernard Sarnat International Prize in Mental Health (Institute of Medicine of the National Academy of Sciences, 2013), the Schizophrenia International Research Society (SIRS) Lifetime Achievement Award (SIRS, 2019) and the Pardes Humanitarian Prize in Mental Health (Brain and Behaviour Research Foundation, 2019).  Mr Matthew Racher is a Certified Recovery Peer Specialist and dedicated advocate for people living with schizophrenia, who is currently studying for his Master of Social Work (MSW) in Miami, Florida. Mr Racher’s aim is to draw upon his own lived experience in recovery from schizophrenia to help others manage and overcome their own mental health challenges. Alongside his involvement in Miami-Dade’s local National Alliance on Mental Illness (NAMI) affiliate, he is also a keen and talented musician, who performs in the band FogDog alongside Mr Carlos Larrauri and whose music can be heard in this podcast.

Dr John Kane, a clinical expert in schizophrenia, discusses cognitive impairments in schizophrenia with fellow expert Dr Philip D. Harvey and patient advocate and mental health clinician, Mr Carlos Larrauri, who was diagnosed with schizophrenia. The podcast aims to raise awareness of the unmet need to address cognitive impairments associated with schizophrenia (CIAS) as well as the challenges/opportunities faced by patients and clinicians regarding assessments and treatments. The authors emphasize the importance of a treatment focus on daily functioning, in parallel with cognitive symptoms, to mitigate impairments and improve overall outcomes. Mr Larrauri presents the patient perspective and shares his experiences of how psychosocial support and cognitive training can benefit recovery and help patients achieve their goals. Author Biographies Dr John Kane is Professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, a recipient of the Arthur P. Noyes Award in Schizophrenia, the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz E. Lehmann Research Award from New York State, and the Dean Award from the American College of Psychiatrists. Dr Philip D. Harvey is Leonard M. Miller Professor of Psychiatry, vice chair for research, and director of the Division of Psychology at the University of Miami Miller School of Medicine, and has also received a number of awards for research and has authored over 1,000 scientific papers and abstracts and written over 60 book chapters.  Mr Carlos A. Larrauri, MSN, is a mental health clinician, and member of the National Alliance on Mental Illness (NAMI) Board of Directors who was diagnosed with schizophrenia at 23 years of age. He has previously published on cognition and functioning in schizophrenia with Dr. Harvey, and is currently pursuing a law degree at the University of Michigan Law School, and a concurrent master’s in public administration at the Harvard Kennedy School, where he is a Zuckerman Fellow at Harvard’s Center for Public Leadership. He also writes original music and performs in the band FogDog alongside Mr Matthew Racher, whose music can be heard in this podcast.

In the final episode of Season 4, Dr Surya Bhatt is here to discuss the influence of continued smoking on COPD with Dr Richard Russell. They will discuss how smoking can impact treatment decisions, how we can get our patients to stop smoking and the effects smoking can have on COPD outcomes.1–3 Dr Russell will then dive into a new publication on the impact of air quality on exacerbations during the COVID-19 lockdown,4 before highlighting what’s hot on social media. This week, the focus is on singing for lung health and how to better engage our patients! 1. Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available at: https://goldcopd.org/. Last accessed: November 2022; 2. Sonnex K, et al. BMJ Open 2020;10:e037509; 3. Au DH, et al. J Gen Intern Med 2009;24:457–463; 4. Montiel-Lopez F, et al. ERJ Open Res 2022;8:00183–2022. Disclosure: Dr Surya Bhatt Dr Bhatt has received grants from the National Institutes of Health, has served on advisory boards for Boehringer Ingelheim and Sanofi/Regeneron and has received continuing medical education fees from Integrity CE within the past 3 years. Bio: Dr Surya Bhatt Dr Surya Bhatt is an Associate Professor of Medicine in the Division of Pulmonary, Allergy and Critical Care Medicine at the University of Alabama at Birmingham (UAB), and is the Director of the UAB Lung Imaging Lab. He also serves as the Medical Director of the UAB Pulmonary Function Testing and Exercise Physiology Lab, and as the Medical Director of the UAB Telehealth and Center-based Pulmonary Rehabilitation programmes. His research focus is on developing new imaging metrics for the early diagnosis, phenotyping and precision-based therapy of COPD.   This series of podcasts are intended for healthcare professionals only. The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief. Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Dr Richard Russell is joined this week by Professor James Chalmers, the Asthma and Lung UK Chair of Respiratory Research at the University of Dundee, Scotland, and Honorary consultant physician at Ninewells Hospital, to discuss the role of the lung microbiome in respiratory disease and the influence it may have on the management of COPD.1–3 Dr Russell will then share insights from an interesting new editorial which explores strategies implemented in the management of chronic respiratory disease in Finland from 1996–2018. 4 Finally, we delve into the social media hot topic of the week: advance care planning in COPD. Be sure to subscribe to the Medical Insider COPD podcast and never miss an episode! 1. Global Initiative for Chronic Obstructive Lung Disease 2022. Available at: here Last accessed: September 2022 2. Keir H, Contoli M, and Chalmers JD. Biomedicines 2021;9:1312; 3. Keir H, et al. Am J Respir Crit Care Med 2022;205:A5567; 4. Tiina M, et al. Eur Respir J 2022;60:2200318 Disclosures Professor James Chalmers Professor James Chalmers has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Insmed, Janssen, Novartis and Zambon. He has also received research grant support from AstraZeneca, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Insmed and Novartis. Bios: Professor James Chalmers Professor James Chalmers is the Asthma and Lung UK Chair of Respiratory Research at the University of Dundee, Scotland, and an Honorary consultant physician at Ninewells Hospital. His clinical and research interests are in difficult airways diseases, particularly bronchiectasis and COPD. He chaired the 2017 European Respiratory Society bronchiectasis guidelines and was also involved with 2020 Guidelines on inhaled corticosteroid use in COPD and the 2021 COVID-19 management guidelines. He is also deputy chief editor of the European Respiratory Journal and a member of the Editorial Board for the Medical Insider COPD Podcast series.   This series of podcasts are intended for healthcare professionals only. The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief. Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Dr Richard Russell is joined this week by Professor David Newby, the Chair of Cardiology at the University of Edinburgh, Scotland, to discuss the overlap between COPD and cardiovascular disease in clinical practice. Listen as they explore the similarities between risk factors and patient presentation, which treatments are the most effective, and how cardiologists and respiratory physicians can work together to be the best for their patients. 1-4 Dr Russell will then highlight an interesting new paper on the associations between COPD and severe pulmonary hypertension,5 before delving into the social media hot topic of the week: mucus in the lungs. 1. Morgan AD, et al. Ther Adv Respir Dis 2018;12:1753465817750524; 2. Rabe KF, et al. Eur Respir Rev 2018;27:180057; 3. Visseren FLJ, et al. Eur Heart J 2021;42:3227–3337; 4. Rogliani P, et al. Int J Chron Obstruct Pulmon Dis 2017;12:3469–3485; 5. Dauriat G, et al. Eur Respir J 2022;60:2102897 Disclosures Professor David Newby Professor Newby reports fees from Amgen (consultancy, research projects), AstraZeneca (meetings, consultancy, lectures, research projects), Boehringer Ingelheim (meetings, lectures, research projects), Bristol Myers Squibb (meetings, consultancy, research projects), British Medical Journal (Deputy Editor of Heart), Cleerly (talks), Elsevier (books), Eli Lilly (meetings, consultancy), GE Healthcare (research projects), GlaxoSmithKline (meetings, consultancy, lectures, trial steering committee, research projects), Roche (research projects), IC Targets (research projects), Inositec (consultancy, research projects), Janssen/Johnson & Johnson (meetings, consultancy, research projects), Life Molecular Imaging (research projects), Medtronic (meetings), Nordic Pharma (research projects), Novartis (consultancy, research projects), Pfizer (meetings, consultancy, lectures, research projects), Sanofi (meetings, consultancy, lectures, research projects), Siemens (research projects), Silence Therapeutics (consultancy), Spacelabs Healthcare (research projects), Toshiba (meetings, consultancy, lectures, research projects), UCB Pharma (consultancy, data monitoring committee), Wyeth (research projects) and Zealand Pharma (consultancy). Bios: Professor David Newby Professor David Newby is the British Heart Foundation Duke of Edinburgh Chair of Cardiology at the University of Edinburgh, Director of the Edinburgh Clinical Research Facility, Director of the Edinburgh Imaging Facilities and a Consultant Interventional Cardiologist at the Royal Infirmary of Edinburgh. He has major interests in experimental medicine, advanced imaging and clinical trials in cardiovascular disease. He has investigated the adverse cardiovascular effects of air pollution as well as the interplay between cardiovascular and respiratory disease.   This series of podcasts are intended for healthcare professionals only. The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief. Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

This week's guest on the Medical Insider COPD podcast is Professor Eric Bateman, a Chest Physician and Professor of Respiratory Medicine at the University of Cape Town, South Africa. Join him and Dr Richard Russell as they discuss the barriers impeding implementation of global COPD recommendations in low- and middle-income countries (LMICs) and how global guidelines might better cater to LMICs,1,2 highlighting the importance of treatment accessibility worldwide. 1,3 Dr Russell will then present important takeaways from a new and exciting publication on the use of diaphragmatic movement as a prognostic marker of COPD. 4 This will be followed by a dive into social media, where patients with COPD are discussing the safety of resuming travelling. Don’t miss out on this exciting episode of the Medical Insider COPD and remember to subscribe! 1. Hurst JR, et al. Ann Am Thorac Soc 2021;18:1269–1277; 2. Global Initiative for Chronic Obstructive Lung Disease. 2022 Update. Available at: here . Last accessed: July 2022; 3. Brakema EA, et al. NPJ Prim Care Respir Med 2019;29:6; 4. Mekov E, et al. Int J Chron Obstruct Pulmon Dis 2022;17:1041–1050. Disclosures Professor Eric Bateman Eric Bateman has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Hikma Pharma, Menarini, Novartis, Regeneron and Sanofi Genzyme. He also reports consulting fees from AstraZeneca, Novartis, Regeneron and Sanofi Genzyme in the past 3 years. Bios: Professor Eric Bateman Professor Eric Bateman is the founder and former director of the University of Cape Town Lung Institute and former Head of the Division of Pulmonology at the University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa. His primary research interests include the pharmacology and management of asthma and COPD, as well as community-based interventions to improve the care of patients. He has published more than 370 papers in international peer-reviewed journals. He is a member of both the Board and the Science Committee of the Global Initiative for Asthma and has served as President of the South African Thoracic Society. He has received numerous awards including the President’s Award from the European Thoracic Society for his global contribution to Respiratory Medicine (2012), South Africa’s National Science and Technology Forum BHP-Billiton Lifetime Award for Outstanding Contribution to Science, Engineering, Technology and Innovation (2014) and the World Lung Health Award from the American Thoracic Society (2018).   This series of podcasts are intended for healthcare professionals only. The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief. Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

In this episode of the Medical Insider COPD podcast, Dr Richard Russell is joined by Professor Sinthia Bosnic-Anticevich to explore the importance of inspiratory effort in COPD. 1 They will discuss the different types of inhalers available, the impact of suboptimal inspiratory effort on the management of COPD and the key considerations for clinicians when prescribing an inhaler. 2–4 Dr Russell will also share highlights from a recent publication on dust allergen sensitisation, modifying home circumstances and the impact of these factors on exacerbations, 5 before sharing this week’s social media hot topic – fatigue in COPD. Subscribe now and join us again next time on the Medical Insider COPD! 1. Kocks J, et al. ERS 2021:OA81 (poster presentation); 2. Ghosh S, et al. J Aerosol Med Pulm Drug Deliv 2017;30:381-387; 3. Loh CH, et al. Ann Am Thorac Soc 2017;14:1305-1311; 4. Usmani O. Ther Clin Risk Manag 2019;5:461-472; 5. Putcha N, et al. Am J Respir Crit Care Med 2022;205:412-420. Disclosures Professor Sinthia Bosnic-Anticevich Professor Sinthia Bosnic-Anticevich reports Advisory Board Consultancies and lecture honorarium from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mundipharma, Mylan, Sanofi and TEVA Pharmaceuticals. Bios: Professor Sinthia Bosnic-Anticevich Sinthia Bosnic-Anticevich is a Professor at Sydney Pharmacy School, University of Sydney, Australia, the Research Leader of the Quality Use of Respiratory Medicines Group and the Director of Development at the Woolcock Institute of Medical Research. Alongside this, she is a Specialist Respiratory Pharmacist at Woolcock Respiratory Clinic, Australia, and Associate Editor of several high impact international respiratory journals including European Respiratory Review and European Respiratory Society Monograph.   This series of podcasts are intended for healthcare professionals only. The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief. Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Dr Richard Russell is joined by Professor Antonio Anzueto in this episode of the Medical Insider COPD podcast to talk about real-world evidence and the gaps it can fill in the world of COPD research. Listen as they compare the finding from randomised controlled trials with real-world data and discuss how guidelines can be implemented in clinical practice. 1-3 Dr Russell will also highlight a new and exciting publication on the role of blood eosinophils in the development of obstructive lung disease, 4 before delving into this week’s social media hot topic of COPD fatigue. Make sure to subscribe so you don’t miss out! 1. Quint JK, et al. Adv Ther 2021;38:2249–2270; 2. Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 2022; 3. Halpin DMG, et al. Respir Res 2016;17:120; 4. Park HY, et al. Eur Respir J 2021;58:2003823. Disclosures Dr Antonio Anzueto Dr Anzueto reports consultancy and advisory board membership fees from AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva Pharma; he also reports research grants from GlaxoSmithKline. Dr Anzueto is a member of the ATS/ERS Task Force on COPD, is a member of the GOLD Scientific Committee and is a member of the Infectious Diseases Society of America/ATS Community-Acquired Pneumonia Guidelines Committee. Bios: Dr Antonio Anzueto Antonio R. Anzueto, MD, is a Professor of Pulmonary/Critical Care in the department of Medicine at the University of Texas Health, San Antonio. He is Chief in the Pulmonary Section, Audie L. Murphy Memorial Veterans’ Hospital Division in San Antonio, Texas, where he also serves as Medical Director of the Respiratory Therapy Department and Medical Director of the Pulmonary Function Laboratory. Dr Anzueto currently serves on the editorial board of the American Journal of Respiratory and Critical Care Medicine, the American College of Chest Physicians (CHEST) journal, the COPD journal and the Respiratory Research journal. He is affiliated with several professional organisations, including the European Respiratory Society (ERS), the American Thoracic Society (ATS) and Global Obstructive Lung Disease (GOLD) initiative.   This series of podcasts are intended for healthcare professionals only. The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief. Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

To begin this episode of the Medical Insider COPD podcast, Dr Richard Russell is joined by Professor James Chalmers once more to delve into the topic of bronchiectasis. Specifically, they will be discussing how patients with bronchiectasis compare with patients with COPD, what treatments are the most appropriate and what the guidelines recommend. 1–3 Dr Russell also presents a new publication looking into the impact of air pollution on the respiratory health of patients with COPD, 4 and highlights what patients have been talking about on social media this week, including vaccination and exercise programmes during the COVID-19 pandemic. 1. Chalmers JD, et al. Am J Respir Crit Care Med 2018;197:1410–1420; 2. Polverino E, et al. Eur Respir J 2017;50:1700629; 3. Polverino E, et al. Eur Respir J 2018;51:1800328; 4. Evangelopoulos D, et al. Eur Respir J 2021;58:2003432. Disclosures Professor James Chalmers Professor James Chalmers has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Insmed, Janssen, Novartis and Zambon. He has also received research grant support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Insmed and Novartis. Bios: Professor James Chalmers Professor James Chalmers is the Asthma and Lung UK Chair of Respiratory Research at the University of Dundee, Scotland, and an Honorary consultant physician at Ninewells Hospital. His clinical and research interests are in difficult airways diseases, particularly bronchiectasis and COPD. He chaired the 2017 European Respiratory Society bronchiectasis guidelines, with 2020 Guidelines on inhaled corticosteroid use in COPD and the 2021 COVID-19 management guidelines. He is also deputy chief editor of the European Respiratory Journal.   This series of podcasts are intended for healthcare professionals only. The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief. Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

On the Medical Insider COPD Podcast this week, Dr Richard Russell is joined by Professor MeiLan Han from the University of Michigan in the United States. She will be discussing early COPD and how imaging can play a role in the diagnosis and management of COPD. 1-3 Listen as she explores the benefits of identifying COPD earlier in the course of the disease as well as in younger patients, 1,2 delving into her experience working on large long-term cohort studies. 4 Dr Russell will then present a new publication on the use of beta-blockers in patients with COPD following a myocardial infarction. 5 Stay to the end to hear Dr Russell’s thoughts on the ‘invisible epidemic’ of COPD and how we can increase awareness of the disease across the globe! 1 Labaki WW & Han MK. Ann Am Thorac Soc 2018;15:S243-S248; 2 Han MK, et al. Am J Respir Crit Care Med 2020;203:414-423; 3 Ash SY, et al. Radiology 2021;299:222-231; 4 Lowe KE, et al. Chronic Obstrust Pulmon Dis 2019;6:384-399; 5 Rasmussen DB, et al. Thorax 2020;75:928-933. Disclosures MeiLan Han reports personal fees from Aerogen, Altesa Biopharma, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, DevPro, GlaxoSmithKline, Integrity, Medscape, Merck, Mylan, Novartis, Polarian, Pulmonx, Regeneron, Sanofi, Teva, United Therapeutics, UpToDate and Verona. She has received either in kind research support or funds paid to the institution from AstraZeneca, Biodesix, Boehringer Ingelheim, Gala Therapeutics, NIH, Novartis, Nuvaira, Sanofi, Sunovion, the COPD Foundation and the American Lung Association. She has participated in Data Safety Monitoring Boards for Novartis and Medtronic with funds paid to the institution. She has received stock options from Meissa Vaccines and Altesa Biopharma Bio: Professor MeiLan Han MeiLan Han is a Professor of Internal Medicine and Chief of the Division of Pulmonary and Critical Care Medicine at the University of Michigan Health System. She belongs to numerous professional societies including the American Thoracic Society and the European Respiratory Society. She is also a Deputy Editor for the American Journal of Respiratory and Critical Care Medicine and serves as a member of the Global Obstructive Lung Disease (GOLD) scientific committee. She is also author of a book for the lay public, Breathing Lessons, a Doctor’s Guide to Lung Health.   This series of podcasts are intended for healthcare professionals only. The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief. Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

This episode’s guest on the Medical Insider COPD podcast is Dr Barbara Yawn, a primary care physician and COPD clinical researcher. Join her and Dr Richard Russell as they explore the impact of breathlessness from the patient perspective, discussing physical activity, pharmacotherapy and mortality. 1-4 Dr Russell will then present the key takeaways from a new and exciting publication on the real-world impact of exacerbations on quality of life. 5 This is followed by a dive into the world of social media, where patients with COPD are discussing the use of face masks to prevent the transmission of respiratory viruses this winter. 1 Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 2022 2 Hutchinson A, et al. Eur Respir J 2018;51:1701477; 3 Waschki B, et al. Chest 2011;140:331-332; 4 Watz H, et al. Eur Respir J 2014;44:1521; 5 Stöber A, et al. Int J Chron Obstruct Pulmon Dis 2021;16:2637-2651 Disclosures Dr Yawn reports advisory board membership and consultancy fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Teva. She also reports research support for investigator-initiated research from GlaxoSmithKline. Bio: Dr Barbara Yawn Dr Barbara Yawn (MD MSc FAAFP) is Professor of Family and Community Health at the University of Minnesota, having retired as Director of Research at the Olmsted Medical Center and as Chief Science Officer of the COPD Foundation, USA. She is the Editor-in-Chief and Founding Editor of Respiratory Medicine Case Report Journal. Dr Yawn began her career in rural family medicine, moving on to found a research programme at the Olmsted Medical Center. She has served on numerous US national guideline panels. She has published over 400 peer-reviewed articles, several books and book chapters and is a frequent speaker at respiratory conferences in the US and internationally.   This series of podcasts are intended for healthcare professionals only. The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief. Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.